Age‐varying effects of cannabis use frequency and disorder on symptoms of psychosis, depression and anxiety in adolescents and adults

Aims We tested the age‐varying associations of cannabis use (CU) frequency and disorder (CUD) with psychotic, depressive and anxiety symptoms in adolescent and adult samples. Moderating effects of early onset (≤ 15 years) and sex were tested. Design Time‐varying effect models were used to assess the...

Full description

Saved in:
Bibliographic Details
Published inAddiction (Abingdon, England) Vol. 114; no. 2; pp. 278 - 293
Main Authors Leadbeater, Bonnie J., Ames, Megan E., Linden‐Carmichael, Ashley N.
Format Journal Article
LanguageEnglish
Published England Blackwell Publishing Ltd 01.02.2019
John Wiley and Sons Inc
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Aims We tested the age‐varying associations of cannabis use (CU) frequency and disorder (CUD) with psychotic, depressive and anxiety symptoms in adolescent and adult samples. Moderating effects of early onset (≤ 15 years) and sex were tested. Design Time‐varying effect models were used to assess the significance of concurrent associations between CU and CUD and symptoms of psychosis, depression and anxiety at each age. Setting and Participants Adolescent data (V‐HYS; n = 662) were collected from a randomly recruited sample of adolescents in Victoria, British Columbia, Canada during a 10‐year period (2003–13). Adult cross‐sectional data (NESARC‐III; n = 36 309) were collected from a representative sample from the United States (2012–13). Measurements Mental health symptoms were assessed using self‐report measures of diagnostic symptoms. CU was based on frequency of past‐year use. Past‐year CUD was based on DSM‐5 criteria. Findings For youth in the V‐HYS, CU was associated with psychotic symptoms following age 22 [b = 0.13, 95% confidence interval (CI) = 0.002, 0.25], with depressive symptoms from ages 16–19 and following age 25 (b = 0.17, 95% CI = 0.003, 0.34), but not with anxiety symptoms. CUD was associated with psychotic symptoms following age 23 (b = 0.51, 95% CI = 0.01, 1.01), depressive symptoms at ages 19–20 and following age 25 (b = 0.71, 95% CI = 0.001, 1.42) and anxiety symptoms ages 26–27 only. For adults in the NESARC‐III, CU was associated with mental health symptoms at most ages [e.g. psychotic symptoms; age 18 (b = 0.22, 95% CI = 0.10, 0.33) to age 65 (b = 0.36, 95% CI = 0.16, 0.56)]. CUD was associated with all mental health symptoms across most ages [e.g. depressive symptoms; age 18 (b = 0.96, 95% CI = 0.19, 1.73) to age 61 (b = 1.11, 95% CI = 0.01, 2.21)]. Interactions with sex show stronger associations for females than males in young adulthood [e.g. V‐HYS: CUD × sex interaction on psychotic symptoms significant after age 26 (b = 1.12, 95% CI = 0.02, 2.21)]. Findings were not moderated by early‐onset CU. Conclusions Significant associations between cannabis use (CU) frequency and disorder (CUD) and psychotic and depressive symptoms in late adolescence and young adulthood extend across adulthood, and include anxiety.
AbstractList AimsWe tested the age‐varying associations of cannabis use (CU) frequency and disorder (CUD) with psychotic, depressive and anxiety symptoms in adolescent and adult samples. Moderating effects of early onset (≤ 15 years) and sex were tested.DesignTime‐varying effect models were used to assess the significance of concurrent associations between CU and CUD and symptoms of psychosis, depression and anxiety at each age.Setting and ParticipantsAdolescent data (V‐HYS; n = 662) were collected from a randomly recruited sample of adolescents in Victoria, British Columbia, Canada during a 10‐year period (2003–13). Adult cross‐sectional data (NESARC‐III; n = 36 309) were collected from a representative sample from the United States (2012–13).MeasurementsMental health symptoms were assessed using self‐report measures of diagnostic symptoms. CU was based on frequency of past‐year use. Past‐year CUD was based on DSM‐5 criteria.FindingsFor youth in the V‐HYS, CU was associated with psychotic symptoms following age 22 [b = 0.13, 95% confidence interval (CI) = 0.002, 0.25], with depressive symptoms from ages 16–19 and following age 25 (b = 0.17, 95% CI = 0.003, 0.34), but not with anxiety symptoms. CUD was associated with psychotic symptoms following age 23 (b = 0.51, 95% CI = 0.01, 1.01), depressive symptoms at ages 19–20 and following age 25 (b = 0.71, 95% CI = 0.001, 1.42) and anxiety symptoms ages 26–27 only. For adults in the NESARC‐III, CU was associated with mental health symptoms at most ages [e.g. psychotic symptoms; age 18 (b = 0.22, 95% CI = 0.10, 0.33) to age 65 (b = 0.36, 95% CI = 0.16, 0.56)]. CUD was associated with all mental health symptoms across most ages [e.g. depressive symptoms; age 18 (b = 0.96, 95% CI = 0.19, 1.73) to age 61 (b = 1.11, 95% CI = 0.01, 2.21)]. Interactions with sex show stronger associations for females than males in young adulthood [e.g. V‐HYS: CUD × sex interaction on psychotic symptoms significant after age 26 (b = 1.12, 95% CI = 0.02, 2.21)]. Findings were not moderated by early‐onset CU.ConclusionsSignificant associations between cannabis use (CU) frequency and disorder (CUD) and psychotic and depressive symptoms in late adolescence and young adulthood extend across adulthood, and include anxiety.
We tested the age-varying associations of cannabis use (CU) frequency and disorder (CUD) with psychotic, depressive and anxiety symptoms in adolescent and adult samples. Moderating effects of early onset (≤ 15 years) and sex were tested. Time-varying effect models were used to assess the significance of concurrent associations between CU and CUD and symptoms of psychosis, depression and anxiety at each age. Adolescent data (V-HYS; n = 662) were collected from a randomly recruited sample of adolescents in Victoria, British Columbia, Canada during a 10-year period (2003-13). Adult cross-sectional data (NESARC-III; n = 36 309) were collected from a representative sample from the United States (2012-13). Mental health symptoms were assessed using self-report measures of diagnostic symptoms. CU was based on frequency of past-year use. Past-year CUD was based on DSM-5 criteria. For youth in the V-HYS, CU was associated with psychotic symptoms following age 22 [b = 0.13, 95% confidence interval (CI) = 0.002, 0.25], with depressive symptoms from ages 16-19 and following age 25 (b = 0.17, 95% CI = 0.003, 0.34), but not with anxiety symptoms. CUD was associated with psychotic symptoms following age 23 (b = 0.51, 95% CI = 0.01, 1.01), depressive symptoms at ages 19-20 and following age 25 (b = 0.71, 95% CI = 0.001, 1.42) and anxiety symptoms ages 26-27 only. For adults in the NESARC-III, CU was associated with mental health symptoms at most ages [e.g. psychotic symptoms; age 18 (b = 0.22, 95% CI = 0.10, 0.33) to age 65 (b = 0.36, 95% CI = 0.16, 0.56)]. CUD was associated with all mental health symptoms across most ages [e.g. depressive symptoms; age 18 (b = 0.96, 95% CI = 0.19, 1.73) to age 61 (b = 1.11, 95% CI = 0.01, 2.21)]. Interactions with sex show stronger associations for females than males in young adulthood [e.g. CUD × sex interaction on psychotic symptoms significant after age 26 (b = 1.12, 95% CI = 0.02, 2.21)]. Findings were not moderated by early-onset CU. Significant associations between cannabis use (CU) frequency and disorder (CUD) and psychotic and depressive symptoms in late adolescence and young adulthood extend across adulthood, and include anxiety.
Aims We tested the age‐varying associations of cannabis use (CU) frequency and disorder (CUD) with psychotic, depressive and anxiety symptoms in adolescent and adult samples. Moderating effects of early onset (≤ 15 years) and sex were tested. Design Time‐varying effect models were used to assess the significance of concurrent associations between CU and CUD and symptoms of psychosis, depression and anxiety at each age. Setting and Participants Adolescent data (V‐HYS; n = 662) were collected from a randomly recruited sample of adolescents in Victoria, British Columbia, Canada during a 10‐year period (2003–13). Adult cross‐sectional data (NESARC‐III; n = 36 309) were collected from a representative sample from the United States (2012–13). Measurements Mental health symptoms were assessed using self‐report measures of diagnostic symptoms. CU was based on frequency of past‐year use. Past‐year CUD was based on DSM‐5 criteria. Findings For youth in the V‐HYS, CU was associated with psychotic symptoms following age 22 [b = 0.13, 95% confidence interval (CI) = 0.002, 0.25], with depressive symptoms from ages 16–19 and following age 25 (b = 0.17, 95% CI = 0.003, 0.34), but not with anxiety symptoms. CUD was associated with psychotic symptoms following age 23 (b = 0.51, 95% CI = 0.01, 1.01), depressive symptoms at ages 19–20 and following age 25 (b = 0.71, 95% CI = 0.001, 1.42) and anxiety symptoms ages 26–27 only. For adults in the NESARC‐III, CU was associated with mental health symptoms at most ages [e.g. psychotic symptoms; age 18 (b = 0.22, 95% CI = 0.10, 0.33) to age 65 (b = 0.36, 95% CI = 0.16, 0.56)]. CUD was associated with all mental health symptoms across most ages [e.g. depressive symptoms; age 18 (b = 0.96, 95% CI = 0.19, 1.73) to age 61 (b = 1.11, 95% CI = 0.01, 2.21)]. Interactions with sex show stronger associations for females than males in young adulthood [e.g. V‐HYS: CUD × sex interaction on psychotic symptoms significant after age 26 (b = 1.12, 95% CI = 0.02, 2.21)]. Findings were not moderated by early‐onset CU. Conclusions Significant associations between cannabis use (CU) frequency and disorder (CUD) and psychotic and depressive symptoms in late adolescence and young adulthood extend across adulthood, and include anxiety.
Abstract Aims We tested the age‐varying associations of cannabis use (CU) frequency and disorder (CUD) with psychotic, depressive and anxiety symptoms in adolescent and adult samples. Moderating effects of early onset (≤ 15 years) and sex were tested. Design Time‐varying effect models were used to assess the significance of concurrent associations between CU and CUD and symptoms of psychosis, depression and anxiety at each age. Setting and Participants Adolescent data (V‐HYS; n  = 662) were collected from a randomly recruited sample of adolescents in Victoria, British Columbia, Canada during a 10‐year period (2003–13). Adult cross‐sectional data (NESARC‐III; n  = 36 309) were collected from a representative sample from the United States (2012–13). Measurements Mental health symptoms were assessed using self‐report measures of diagnostic symptoms. CU was based on frequency of past‐year use. Past‐year CUD was based on DSM‐5 criteria. Findings For youth in the V‐HYS, CU was associated with psychotic symptoms following age 22 [ b  = 0.13, 95% confidence interval (CI) = 0.002, 0.25], with depressive symptoms from ages 16–19 and following age 25 ( b  = 0.17, 95% CI = 0.003, 0.34), but not with anxiety symptoms. CUD was associated with psychotic symptoms following age 23 ( b  = 0.51, 95% CI = 0.01, 1.01), depressive symptoms at ages 19–20 and following age 25 ( b  = 0.71, 95% CI = 0.001, 1.42) and anxiety symptoms ages 26–27 only. For adults in the NESARC‐III, CU was associated with mental health symptoms at most ages [e.g. psychotic symptoms; age 18 ( b  = 0.22, 95% CI = 0.10, 0.33) to age 65 ( b  = 0.36, 95% CI = 0.16, 0.56)]. CUD was associated with all mental health symptoms across most ages [e.g. depressive symptoms; age 18 ( b  = 0.96, 95% CI = 0.19, 1.73) to age 61 ( b  = 1.11, 95% CI = 0.01, 2.21)]. Interactions with sex show stronger associations for females than males in young adulthood [e.g. V‐HYS: CUD × sex interaction on psychotic symptoms significant after age 26 ( b  = 1.12, 95% CI = 0.02, 2.21)]. Findings were not moderated by early‐onset CU. Conclusions Significant associations between cannabis use (CU) frequency and disorder (CUD) and psychotic and depressive symptoms in late adolescence and young adulthood extend across adulthood, and include anxiety.
Author Leadbeater, Bonnie J.
Ames, Megan E.
Linden‐Carmichael, Ashley N.
AuthorAffiliation 1 Department of Psychology University of Victoria Victoria BC Canada
2 Department of Biobehavioral Health, Edna Bennett Pierce Prevention Research Center, 303 Biobehavioral Health The Pennsylvania State University University Park PA, USA
AuthorAffiliation_xml – name: 1 Department of Psychology University of Victoria Victoria BC Canada
– name: 2 Department of Biobehavioral Health, Edna Bennett Pierce Prevention Research Center, 303 Biobehavioral Health The Pennsylvania State University University Park PA, USA
Author_xml – sequence: 1
  givenname: Bonnie J.
  surname: Leadbeater
  fullname: Leadbeater, Bonnie J.
  organization: University of Victoria
– sequence: 2
  givenname: Megan E.
  orcidid: 0000-0001-7871-7421
  surname: Ames
  fullname: Ames, Megan E.
  email: mames@uvic.ca
  organization: University of Victoria
– sequence: 3
  givenname: Ashley N.
  orcidid: 0000-0001-8187-6538
  surname: Linden‐Carmichael
  fullname: Linden‐Carmichael, Ashley N.
  organization: The Pennsylvania State University
BackLink https://www.ncbi.nlm.nih.gov/pubmed/30276906$$D View this record in MEDLINE/PubMed
BookMark eNp1kc1u1DAUhS1URKeFBS-ALLFCIq3_4sQbpFHLn1SJDawtx76ZusrYwU5asmPHlmfkSfDMlAoWeGNZ97vnHt9zgo5CDIDQc0rOaDnnxrkzKkStHqEV5ZJURAh-hFZEybpiVJBjdJLzDSGkaZV4go45YY1URK7Qj_UGfn3_eWvS4sMGQ9-DnTKOPbYmBNP5jOcMuE_wdYZgF2yCw87nmBwkHAPOy3ac4nbfMubFXsfs82vsYEyQsy_ErsOEbx6mBfvydHGAbCGUMfuSm4cpP0WPezNkeHZ_n6Iv795-vvhQXX16__FifVXZ8iVV8Q4Ed30DTqimdU7UDIjg1rYCutpRaBVhtCEcWKdM7yQXjHeEk65zRkrLT9Gbg-44d1twOxvJDHpMfltWoKPx-t9K8Nd6E2-1rKlijBeBl_cCKZaV5EnfxDmF4lkzKhlvuaSkUK8OlE0x5wT9wwRK9C4zXTLT-8wK--JvSw_kn5AKcH4A7vwAy_-V9Pry8iD5GwVdpuU
CitedBy_id crossref_primary_10_1016_j_jad_2021_11_067
crossref_primary_10_1017_S0033291720005449
crossref_primary_10_1177_1078390320945791
crossref_primary_10_1111_add_16284
crossref_primary_10_1016_j_drugalcdep_2020_108332
crossref_primary_10_1016_j_comppsych_2024_152469
crossref_primary_10_1177_07067437211043393
crossref_primary_10_3390_ijerph191710873
crossref_primary_10_1016_j_neuropharm_2022_109155
crossref_primary_10_1093_ijnp_pyac056
crossref_primary_10_3389_fpsyt_2022_973988
crossref_primary_10_1016_j_drugpo_2021_103381
crossref_primary_10_3390_brainsci12030388
crossref_primary_10_1177_0706743719895195
crossref_primary_10_1007_s40501_020_00202_2
crossref_primary_10_1016_j_psychres_2023_115190
crossref_primary_10_1089_can_2022_0343
crossref_primary_10_2174_0929867328666210623144658
crossref_primary_10_1016_j_drugalcdep_2022_109531
crossref_primary_10_1016_j_josat_2023_209267
crossref_primary_10_1097_CXA_0000000000000124
crossref_primary_10_3389_fpsyt_2020_00859
crossref_primary_10_3390_molecules28062791
crossref_primary_10_1007_s00213_021_06001_8
crossref_primary_10_1016_j_drugalcdep_2019_107719
crossref_primary_10_1080_00221325_2022_2130025
crossref_primary_10_1007_s10578_021_01280_w
crossref_primary_10_1016_j_pmedr_2023_102304
crossref_primary_10_1007_s12325_019_01151_w
crossref_primary_10_1186_s13034_021_00403_4
crossref_primary_10_7759_cureus_27394
crossref_primary_10_1080_09687637_2020_1715920
crossref_primary_10_1007_s00737_022_01210_2
crossref_primary_10_1007_s11469_019_00201_2
crossref_primary_10_1080_10826084_2023_2267111
crossref_primary_10_1080_08897077_2021_1876200
crossref_primary_10_1016_j_janxdis_2023_102808
crossref_primary_10_1177_02698811221108956
crossref_primary_10_3389_fpsyt_2021_625158
crossref_primary_10_3390_ijerph18073652
crossref_primary_10_1007_s11469_022_00956_1
crossref_primary_10_1080_15504263_2023_2226588
crossref_primary_10_1186_s12889_020_09089_3
crossref_primary_10_3390_brainsci10020097
crossref_primary_10_1371_journal_pone_0263533
crossref_primary_10_1080_10826084_2024_2342008
crossref_primary_10_1177_20503245221095228
crossref_primary_10_1159_000530331
crossref_primary_10_1017_S0033291723000399
crossref_primary_10_1016_j_clinthera_2023_04_002
crossref_primary_10_1016_j_neuropharm_2021_108626
crossref_primary_10_1001_jamanetworkopen_2021_13025
crossref_primary_10_1007_s11469_024_01275_3
crossref_primary_10_1016_j_yfrne_2020_100841
crossref_primary_10_1017_S0033291724000990
crossref_primary_10_1097_01_NPR_0000733712_67456_43
crossref_primary_10_3390_epidemiologia5010007
crossref_primary_10_3390_ijms22157861
crossref_primary_10_1523_JNEUROSCI_1165_19_2019
crossref_primary_10_3389_fpubh_2024_1346207
crossref_primary_10_3390_ijms22189989
crossref_primary_10_1007_s40429_022_00461_4
Cites_doi 10.1016/j.jaac.2016.12.014
10.1089/can.2016.0010
10.1186/2042-6410-3-14
10.1016/S0140-6736(11)60512-6
10.1136/jech-2016-208145
10.1111/j.1469-7610.2008.01970.x
10.1001/archpsyc.62.6.593
10.1016/S0140-6736(07)61162-3
10.1111/add.13826
10.1016/B978-0-12-804791-0.00008-2
10.1016/j.jad.2015.12.045
10.1136/bmj.325.7374.1195
10.1038/sj.npp.1301643
10.1111/j.1360-0443.2012.04015.x
10.1037/0021-843X.107.1.128
10.1017/S0954579413000643
10.1016/j.jaac.2010.05.017
10.1016/j.drugalcdep.2012.10.015
10.1176/appi.books.9780890425596
10.1016/j.drugalcdep.2007.08.005
10.1037/0033-295X.115.2.291
10.1007/s00127-002-0541-z
10.1016/j.schres.2006.07.023
10.1080/15374416.2012.694608
10.1080/00952990.2016.1213273
10.1016/S0140-6736(13)61611-6
10.1016/j.bbr.2015.04.008
10.1016/j.addbeh.2015.05.014
10.1037/cbs0000090
10.1136/bmj.325.7374.1212
10.1016/j.drugalcdep.2013.12.013
ContentType Journal Article
Copyright 2018 The Authors. published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction.
2018 The Authors. Addiction published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction.
2019 Society for the Study of Addiction
Copyright_xml – notice: 2018 The Authors. published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction.
– notice: 2018 The Authors. Addiction published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction.
– notice: 2019 Society for the Study of Addiction
DBID 24P
WIN
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7QG
7TK
8BJ
FQK
JBE
K9.
NAPCQ
5PM
DOI 10.1111/add.14459
DatabaseName Wiley-Blackwell Titles (Open access)
Wiley-Blackwell Backfiles (Open access)
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
Animal Behavior Abstracts
Neurosciences Abstracts
International Bibliography of the Social Sciences (IBSS)
International Bibliography of the Social Sciences
International Bibliography of the Social Sciences
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
PubMed Central (Full Participant titles)
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
International Bibliography of the Social Sciences (IBSS)
Neurosciences Abstracts
Animal Behavior Abstracts
DatabaseTitleList ProQuest Health & Medical Complete (Alumni)
MEDLINE

CrossRef
Database_xml – sequence: 1
  dbid: 24P
  name: Wiley Online Library Open Access
  url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html
  sourceTypes: Publisher
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Social Welfare & Social Work
DocumentTitleAlternate Bonnie J. Leadbeater et al
EISSN 1360-0443
EndPage 293
ExternalDocumentID 10_1111_add_14459
30276906
ADD14459
Genre article
Research Support, Non-U.S. Gov't
Multicenter Study
Journal Article
GeographicLocations United States
British Columbia
GeographicLocations_xml – name: British Columbia
– name: United States
GrantInformation_xml – fundername: National Institute on Drug Abuse
  funderid: P50 DA039838
– fundername: Canadian Institutes of Health Research
  funderid: #146615; SHI‐155410; #130500; #192583; #79917; #88476
– fundername: Michael Smith Foundation for Health Research
  funderid: #16637
– fundername: CIHR
  grantid: SHI-155410
– fundername: CIHR
  grantid: 192583
– fundername: Michael Smith Foundation for Health Research
  grantid: 16637
– fundername: NIDA NIH HHS
  grantid: R01 DA039854
– fundername: CIHR
  grantid: 79917
– fundername: CIHR
  grantid: 88476
– fundername: CIHR
  grantid: 130500
– fundername: CIHR
  grantid: 146615
– fundername: NIDA NIH HHS
  grantid: P50 DA039838
– fundername: Canadian Institutes of Health Research
  grantid: #146615; SHI‐155410; #130500; #192583; #79917; #88476
– fundername: Michael Smith Foundation for Health Research
  grantid: #16637
– fundername: National Institute on Drug Abuse
  grantid: P50 DA039838
GroupedDBID ---
..I
.3N
.GA
.GJ
.Y3
0-V
04C
05W
0R~
10A
1OB
1OC
23M
24P
2QV
31~
33P
36B
3SF
3V.
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5HH
5LA
5RE
5VS
66C
6J9
6PF
702
7PT
7RV
7X7
8-0
8-1
8-3
8-4
8-5
88E
8C1
8FI
8FJ
8G5
8UM
930
A01
A03
A8Z
AAESR
AAEVG
AAHHS
AANLZ
AAONW
AASGY
AAWTL
AAXRX
AAZKR
ABCQN
ABCUV
ABDBF
ABEML
ABIVO
ABJNI
ABOCM
ABPVW
ABQWH
ABUWG
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACFBH
ACGFO
ACGFS
ACGOF
ACHQT
ACMXC
ACNCT
ACPOU
ACPRK
ACSCC
ACXBN
ACXQS
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADOJX
ADOZA
ADXAS
ADZJE
ADZMN
ADZOD
AEEZP
AEGXH
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFEBI
AFFNX
AFFPM
AFGKR
AFKRA
AFPWT
AFRAH
AFZJQ
AHBTC
AHEFC
AHMBA
AIACR
AIAGR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ALSLI
ALUQN
AMBMR
AMYDB
AN0
ARALO
ASPBG
ATUGU
AVWKF
AZBYB
AZFZN
AZQEC
AZVAB
BAFTC
BCR
BCU
BDRZF
BEC
BENPR
BFHJK
BGRYB
BHBCM
BKEYQ
BLC
BMSDO
BMXJE
BNQBC
BPHCQ
BROTX
BRXPI
BVXVI
BY8
C45
CAG
CCPQU
COF
CS3
D-6
D-7
D-E
D-F
DC6
DCZOG
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DUUFO
DWQXO
DXH
EAD
EAP
EAS
EBB
EBC
EBD
EBS
EBX
ECF
ECT
EIHBH
EJD
EMB
EMK
EMOBN
EPS
ESI
ESTFP
ESX
EX3
F00
F01
F04
F5P
FD6
FEDTE
FUBAC
FYUFA
FZ0
G-S
GNUQQ
GODZA
GUQSH
H.X
HF~
HGLYW
HMCUK
HVGLF
HZI
HZ~
H~9
IHE
IX1
J0M
J5H
K48
KBYEO
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
M0O
M1P
M2M
M2O
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NAPCQ
NF~
O66
O9-
OIG
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
PALCI
PCD
PQQKQ
PROAC
PSQYO
PSYQQ
Q.N
Q11
QB0
Q~Q
R.K
RIWAO
RJQFR
ROL
RX1
SAMSI
SJFOW
SUPJJ
SV3
TEORI
TUS
UB1
UKHRP
UPT
V8K
V9Y
W8V
W99
WBKPD
WH7
WHWMO
WIH
WIJ
WIK
WIN
WOHZO
WOW
WQ9
WQJ
WRC
WUP
WVDHM
WXI
WXSBR
XG1
XIF
XOL
YFH
YUY
ZGI
ZZTAW
~IA
~WT
ADMHG
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7QG
7TK
8BJ
FQK
JBE
K9.
5PM
ID FETCH-LOGICAL-c4439-3be43df7ed4978dd452e043cc84eb5d1e89021703e2b9afd63423b030bbda66c3
IEDL.DBID 24P
ISSN 0965-2140
IngestDate Tue Sep 17 21:02:46 EDT 2024
Thu Oct 10 18:56:31 EDT 2024
Fri Aug 23 01:13:01 EDT 2024
Wed Oct 16 00:45:08 EDT 2024
Sat Aug 24 00:43:55 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 2
Keywords Adolescence
anxiety
early onset
mental health
cannabis use
cannabis use disorder
marijuana
young adulthood
depression
psychosis
Language English
License Attribution-NonCommercial-NoDerivs
2018 The Authors. Addiction published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction.
This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4439-3be43df7ed4978dd452e043cc84eb5d1e89021703e2b9afd63423b030bbda66c3
ORCID 0000-0001-7871-7421
0000-0001-8187-6538
OpenAccessLink https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fadd.14459
PMID 30276906
PQID 2162383610
PQPubID 37458
PageCount 16
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_6519223
proquest_journals_2162383610
crossref_primary_10_1111_add_14459
pubmed_primary_30276906
wiley_primary_10_1111_add_14459_ADD14459
PublicationCentury 2000
PublicationDate February 2019
PublicationDateYYYYMMDD 2019-02-01
PublicationDate_xml – month: 02
  year: 2019
  text: February 2019
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
– name: Abingdon
– name: Hoboken
PublicationTitle Addiction (Abingdon, England)
PublicationTitleAlternate Addiction
PublicationYear 2019
Publisher Blackwell Publishing Ltd
John Wiley and Sons Inc
Publisher_xml – name: Blackwell Publishing Ltd
– name: John Wiley and Sons Inc
References 2011; 377
2002; 37
2013; 25
2013; 108
2017; 43
2005; 62
1994
2013; 382
2008; 33
2017; 112
2008; 92
2014; 136
2010; 49
2016; 1
2015; 49
2012; 3
2017; 71
2007; 370
2009; 50
2006; 88
2017; 56
1998; 107
2018
2016; 298
2002; 325
2017
1983
2013; 130
2008; 115
2015
2014
2018; 50
2013
2016; 193
2012; 41
e_1_2_7_6_1
Li R. (e_1_2_7_31_1) 2017
e_1_2_7_5_1
e_1_2_7_4_1
e_1_2_7_3_1
e_1_2_7_9_1
e_1_2_7_8_1
e_1_2_7_7_1
e_1_2_7_19_1
e_1_2_7_18_1
e_1_2_7_17_1
e_1_2_7_16_1
e_1_2_7_2_1
e_1_2_7_15_1
e_1_2_7_14_1
e_1_2_7_13_1
e_1_2_7_12_1
e_1_2_7_11_1
e_1_2_7_10_1
e_1_2_7_26_1
e_1_2_7_27_1
Derogatis L. (e_1_2_7_28_1) 1983
e_1_2_7_29_1
e_1_2_7_30_1
e_1_2_7_25_1
e_1_2_7_24_1
e_1_2_7_32_1
e_1_2_7_23_1
e_1_2_7_33_1
e_1_2_7_22_1
e_1_2_7_34_1
e_1_2_7_21_1
e_1_2_7_35_1
e_1_2_7_20_1
e_1_2_7_36_1
e_1_2_7_37_1
References_xml – volume: 33
  start-page: 2505
  year: 2008
  end-page: 2516
  article-title: Blunted psychotomimetic and amnestic effects of Δ‐9‐ tetrahydrocannabinol in frequent users of cannabis
  publication-title: Neuropsychopharmacology
– year: 1983
– volume: 130
  start-page: 101
  year: 2013
  end-page: 108
  article-title: Gender differences in cannabis use disorders: results from the National Epidemiologic Survey of Alcohol and Related Conditions
  publication-title: Drug Alcohol Depend [internet]
– volume: 41
  start-page: 719
  year: 2012
  end-page: 730
  article-title: Co‐occurring trajectories of symptoms of anxiety, depression, and oppositional defiance from adolescence to young adulthood
  publication-title: J Clin Child Adolesc Psychol
– volume: 92
  start-page: 239
  year: 2008
  end-page: 247
  article-title: Likelihood of developing an alcohol and cannabis use disorder during youth: association with recent use and age
  publication-title: Drug Alcohol Depend
– volume: 50
  start-page: 416
  year: 2009
  end-page: 423
  article-title: The brief child and family phone interview (BCFPI): rationale, development, and description of a computerized children's mental health intake and outcome assessment tool
  publication-title: J Child Psychol Psychiatry
– volume: 382
  start-page: 1575
  year: 2013
  end-page: 1586
  article-title: Global burden of disease attributable to mental and substance use disorders: findings from the global burden of disease study 2010
  publication-title: Lancet
– volume: 43
  start-page: 442
  year: 2017
  end-page: 455
  article-title: Cannabis and development of dual diagnoses: a literature review
  publication-title: Am J Drug Alcohol Abuse
– volume: 88
  start-page: 142
  year: 2006
  end-page: 150
  article-title: Disturbances of visual information processing in early states of psychosis and experimental delta‐9‐tetrahydrocannabinol altered states of consciousness
  publication-title: Schizophr Res
– volume: 1
  start-page: 166
  year: 2016
  end-page: 175
  article-title: Sex differences in cannabis use and effects: a cross‐sectional survey of cannabis users
  publication-title: Cannabis Cannabinoid Res
– volume: 50
  start-page: 17
  year: 2018
  end-page: 28
  article-title: Marijuana trajectories in Canadian youth: associations with substance use and mental health
  publication-title: Can J Behav Sci
– volume: 112
  start-page: 1653
  year: 2017
  end-page: 1657
  article-title: Cannabis, psychosis and schizophrenia: unravelling a complex interaction
  publication-title: Addiction
– volume: 49
  start-page: 33
  year: 2015
  end-page: 39
  article-title: Gender differences in the associations among marijuana use, cigarette use, and symptoms of depression during adolescence and young adulthood
  publication-title: Addict Behav
– volume: 25
  start-page: 1325
  year: 2013
  end-page: 1345
  article-title: Adolescent brain development in normality and psychopathology
  publication-title: Dev Psychopathol
– volume: 108
  start-page: 124
  year: 2013
  end-page: 133
  article-title: The persistence of the association between adolescent cannabis use and common mental disorders into young adulthood
  publication-title: Addiction
– volume: 325
  start-page: 1195
  year: 2002
  end-page: 1198
  article-title: Cannabis use and mental health in young people: cohort study
  publication-title: BMJ
– volume: 136
  start-page: 85
  year: 2014
  end-page: 91
  article-title: Investigation of sex‐dependent effects of cannabis in daily cannabis smokers
  publication-title: Drug Alcohol Depend
– year: 2014
– year: 1994
– volume: 370
  start-page: 319
  year: 2007
  end-page: 328
  article-title: Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review
  publication-title: Lancet
– start-page: 183
  year: 2018
  end-page: 197
– volume: 3
  start-page: 14
  year: 2012
  article-title: Sex differences in the neural mechanisms mediating addiction: A new synthesis and hypothesis
  publication-title: Biol Sex Differ
– volume: 325
  start-page: 1212
  year: 2002
  end-page: 1213
  article-title: Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study
  publication-title: BMJ
– volume: 49
  start-page: 980
  year: 2010
  end-page: 989
  article-title: Lifetime prevalence of mental disorders in U.S. adolescents: results from the national comorbidity survey replication‐adolescent supplement (NCS‐A)
  publication-title: J Am Acad Child Adolesc Psychiatry
– volume: 37
  start-page: 199
  year: 2002
  end-page: 206
  article-title: Marijuana use and the risk of major depressive episode: epidemiological evidence from the United States National Comorbidity Survey
  publication-title: Soc Psychiatry Psychiatr Epidemiol
– volume: 107
  start-page: 128
  year: 1998
  end-page: 140
  article-title: Development of depression from preadolescence to young adulthood: emerging gender differences in a 10‐year longitudinal study
  publication-title: J Abnorm Psychol
– volume: 298
  start-page: 15
  year: 2016
  end-page: 26
  article-title: Sex differences in behavior and neural development and their role in adolescent vulnerability to substance use
  publication-title: Behav Brain Res [internet]
– volume: 62
  start-page: 593
  year: 2005
  end-page: 602
  article-title: Lifetime prevalence and age‐of‐onset distributions of DSM‐IV disorders in the National Comorbidity Survey Replication
  publication-title: Arch Gen Psychiatry
– volume: 56
  start-page: 214
  year: 2017
  end-page: 225
  article-title: Evidence for the risks and consequences of adolescent cannabis exposure
  publication-title: J Am Acad Child Adolesc Psychiatry
– volume: 71
  start-page: 811
  year: 2017
  end-page: 816
  article-title: Association of cannabis use with the development of elevated anxiety symptoms in the general population: a meta‐analysis
  publication-title: J Epidemiol Community Health
– year: 2017
– volume: 377
  start-page: 2093
  year: 2011
  end-page: 2102
  article-title: Global burden of disease in young people aged 10–24 years: a systematic analysis
  publication-title: Lancet
– volume: 193
  start-page: 103
  year: 2016
  end-page: 108
  article-title: Cannabis use, depression and anxiety: a 3‐year prospective population‐based study
  publication-title: J Affect Disord
– volume: 115
  start-page: 291
  year: 2008
  end-page: 313
  article-title: The ABCs of depression: integrating affective, biological, and cognitive models to explain the emergence of the gender difference in depression
  publication-title: Psychol Rev
– year: 2015
– year: 2013
– ident: e_1_2_7_6_1
  doi: 10.1016/j.jaac.2016.12.014
– ident: e_1_2_7_19_1
  doi: 10.1089/can.2016.0010
– ident: e_1_2_7_37_1
  doi: 10.1186/2042-6410-3-14
– ident: e_1_2_7_2_1
  doi: 10.1016/S0140-6736(11)60512-6
– ident: e_1_2_7_8_1
  doi: 10.1136/jech-2016-208145
– ident: e_1_2_7_29_1
  doi: 10.1111/j.1469-7610.2008.01970.x
– ident: e_1_2_7_17_1
  doi: 10.1001/archpsyc.62.6.593
– ident: e_1_2_7_33_1
  doi: 10.1016/S0140-6736(07)61162-3
– ident: e_1_2_7_4_1
  doi: 10.1111/add.13826
– volume-title: TVEM (Time‐Varying Effect Model) SAS Macro Users’ Guide
  year: 2017
  ident: e_1_2_7_31_1
  contributor:
    fullname: Li R.
– ident: e_1_2_7_7_1
  doi: 10.1016/B978-0-12-804791-0.00008-2
– ident: e_1_2_7_11_1
  doi: 10.1016/j.jad.2015.12.045
– ident: e_1_2_7_22_1
  doi: 10.1136/bmj.325.7374.1195
– ident: e_1_2_7_15_1
  doi: 10.1038/sj.npp.1301643
– ident: e_1_2_7_10_1
  doi: 10.1111/j.1360-0443.2012.04015.x
– ident: e_1_2_7_20_1
  doi: 10.1037/0021-843X.107.1.128
– ident: e_1_2_7_12_1
  doi: 10.1017/S0954579413000643
– ident: e_1_2_7_18_1
  doi: 10.1016/j.jaac.2010.05.017
– ident: e_1_2_7_36_1
  doi: 10.1016/j.drugalcdep.2012.10.015
– ident: e_1_2_7_25_1
  doi: 10.1176/appi.books.9780890425596
– ident: e_1_2_7_13_1
  doi: 10.1016/j.drugalcdep.2007.08.005
– ident: e_1_2_7_21_1
  doi: 10.1037/0033-295X.115.2.291
– ident: e_1_2_7_14_1
  doi: 10.1007/s00127-002-0541-z
– ident: e_1_2_7_16_1
  doi: 10.1016/j.schres.2006.07.023
– ident: e_1_2_7_24_1
  doi: 10.1080/15374416.2012.694608
– ident: e_1_2_7_5_1
  doi: 10.1080/00952990.2016.1213273
– ident: e_1_2_7_3_1
  doi: 10.1016/S0140-6736(13)61611-6
– ident: e_1_2_7_35_1
  doi: 10.1016/j.bbr.2015.04.008
– ident: e_1_2_7_23_1
  doi: 10.1016/j.addbeh.2015.05.014
– ident: e_1_2_7_30_1
  doi: 10.1037/cbs0000090
– ident: e_1_2_7_27_1
– ident: e_1_2_7_32_1
– ident: e_1_2_7_9_1
  doi: 10.1136/bmj.325.7374.1212
– ident: e_1_2_7_34_1
  doi: 10.1016/j.drugalcdep.2013.12.013
– volume-title: SCL‐90‐R: Administration, Scoring and Procedures: Manual II
  year: 1983
  ident: e_1_2_7_28_1
  contributor:
    fullname: Derogatis L.
– ident: e_1_2_7_26_1
SSID ssj0007894
Score 2.5665305
Snippet Aims We tested the age‐varying associations of cannabis use (CU) frequency and disorder (CUD) with psychotic, depressive and anxiety symptoms in adolescent and...
We tested the age-varying associations of cannabis use (CU) frequency and disorder (CUD) with psychotic, depressive and anxiety symptoms in adolescent and...
Abstract Aims We tested the age‐varying associations of cannabis use (CU) frequency and disorder (CUD) with psychotic, depressive and anxiety symptoms in...
AimsWe tested the age‐varying associations of cannabis use (CU) frequency and disorder (CUD) with psychotic, depressive and anxiety symptoms in adolescent and...
SourceID pubmedcentral
proquest
crossref
pubmed
wiley
SourceType Open Access Repository
Aggregation Database
Index Database
Publisher
StartPage 278
SubjectTerms Adolescence
Adolescent
Adolescents
Adult
Adults
Age
Age differences
Age Distribution
Age of onset
Anxiety
Anxiety disorders
Anxiety Disorders - epidemiology
Anxiety Disorders - etiology
British Columbia - epidemiology
Cannabis
cannabis use
cannabis use disorder
Child & adolescent psychiatry
Cross-Sectional Studies
depression
Depressive Disorder - epidemiology
Depressive Disorder - etiology
Drug abuse
Drug addiction
Drug use
early onset
Females
Humans
Males
Marijuana
Marijuana Abuse - complications
Marijuana Abuse - epidemiology
Marijuana Smoking - epidemiology
Mental depression
Mental disorders
Mental health
Prospective Studies
Psychosis
Psychotic Disorders - epidemiology
Psychotic Disorders - etiology
Psychotic symptoms
Research Report
Research Reports
Sex differences
Symptoms
Teenagers
United States - epidemiology
Young Adult
young adulthood
Young adults
Title Age‐varying effects of cannabis use frequency and disorder on symptoms of psychosis, depression and anxiety in adolescents and adults
URI https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fadd.14459
https://www.ncbi.nlm.nih.gov/pubmed/30276906
https://www.proquest.com/docview/2162383610
https://pubmed.ncbi.nlm.nih.gov/PMC6519223
Volume 114
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3Pa9swFH506WWXsa3d5i4booyywwy1LcsOO4VmoQxaxlhYbka_vJm2comTsdx667V_Y_-SPkm211AGvQjbkoztz-_pk_T0CeBDHmGrkHAeKh2xkMqYhrnmWUhHLFciS2ki7HjHySk7ntGv83S-BZ-7tTBeH6IfcLOW4fy1NXAumntGjoZpZybT0RPYtooxVjg_pt96N5zlbhdEq24SxtiNaGWFbBhPX3WzMXrAMB8GSt4nsK4Fmj6HZy11JGOP9QvY0uYlDP36WvJTn5d8ockB6S7Ui7MduB7_0rdXN3_wNbGNIm30BqlLgp_UcFE1ZNVoUi58RPWacKOIahU5SW1Is764XNYXropfsdVUzSfSB9AaV4Obvzb2k1R4-k8iymdZgY9mF2bTLz-OjsN274VQUuQoYSI0TVSZaWW3oFOKprE-pImUOdUiVZG285MRugsdixEvFbNKggI9hhCKMyaTVzAwtdFvgJRMSiWFkCLJKKbYQ2KpQmciJBOHsQpgvwOhuPQSG0XXNUGkCodUAMMOnqK1sqaIIyRveYIMMIDXHqn-DnY-1oowB5BtYNgXsLramzmm-u30tRmyWmRNAXx0aP__oYrxZOIO9h5f9C08Rc418oHfQxgsFyv9DnnNUrx3_y-mk-_xHZWV-KI
link.rule.ids 230,315,783,787,888,1378,11574,27936,27937,46064,46306,46488,46730
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6VcoALlHdgAQshxIFUTew4WamXFUu1QNsDakUvKPIrsCp1qs0uopx665XfyC9hbCdplwoJcYmSOE4c2zPz2R5_A_C8SNAqUCFibRIeM5WyuDAij9mQF1rmGaPSzXfs7PLJPnt3kB2swGa3FybwQ_QTbk4yvL52Au4mpC9IOUqmW5rMhlfgKoo7dYEbxh_OyaPywodBdPQmcYrjiJZXyPnx9FmXrdEliHnZU_IigvUmaOsmfOoKHzxPDtcXc7mufvzB6_i_f7cGN1psSkahM92CFWNvwyBs4CUfzddKzAx5Qbob9ezwDpyNPptfpz-_4ZfQCJLWPYTUFcE2s0JOG7JoDKlmwWX7hAiriW4pP0ltSXNydDyvj3yWsCWsmTavSO-ha30OYb8751IyxctzDqqQ5BhEmruwv_Vm7_UkboM7xIohCIqpNIzqKjfaxbjTmmWp2WBUqYIZmenEuAXQBPWRSeVQVJo7qkKJKklKLThX9B6s2tqaB0AqrpRWUipJc4ZHHILxTKO2korLjVRH8Kxr5PI4cHiU3dgHq7n01RzBoGv-shXjpkwTRIcFRYgZwf3QE_o3uAVfx_IcQb7UR_oHHHH3coqdfvEE3hxhM8KyCF76LvD3QpWj8difPPz3R5_Ctcnezna5_Xb3_SO4jgBvGLzMB7A6ny3MYwRRc_nEy8pvQ-Qb2A
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1NT9wwEB1RKqFeUCm0DSythSrEoZFI4jhZcVqxrOgX4gCCW-Sv0FWLs9osqNy4ceU38ksY20nKClXqJUriOEryMjPP9vgZ4FMeYVRIOA-VjlhIZUzDXPMspH2WK5GlNBG2v-PHETs8pV_P0_MF2Gvnwnh9iK7DzVqG89fWwCeqfGLkaJh2ZDLtv4CXFGm4Fc6P6XHnhrPcrYJo1U3CGJsRjayQTePpqs4Ho2cM83mi5FMC6yLQ6DUsN9SRDDzWK7CgzRvo-fm15Ez_LvlUk23Snqimv1bhbnChH27vr_E1MUaRJnuDVCXBT2q4GNfkqtaknPqM6hvCjSKqUeQklSH1zeVkVl26Kn7GVj2uP5Mugda4Gtz8sbmfZIyHfyWifJEV-KjX4HR0cLJ_GDZrL4SSIkcJE6FpospMK7sEnVI0jfUuTaTMqRapirQdn4zQXehY9HmpmFUSFOgxhFCcMZm8hUVTGf0eSMmkVFIIKZKM4hZbSCxV6EyEZGI3VgFstSAUEy-xUbRNE0SqcEgF0GvhKRorq4s4QvKWJ8gAA3jnkeruYMdjrQhzANkcht0FVld7vsSMfzp9bYasFllTADsO7X8_VDEYDt3O-v9f-hGWjoej4vuXo28b8ArpV9_ngPdgcTa90ptIcWbig_uVHwGVwfpN
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Age-varying+effects+of+cannabis+use+frequency+and+disorder+on+symptoms+of+psychosis%2C+depression+and+anxiety+in+adolescents+and+adults&rft.jtitle=Addiction+%28Abingdon%2C+England%29&rft.au=Leadbeater%2C+Bonnie+J&rft.au=Ames%2C+Megan+E&rft.au=Linden-Carmichael%2C+Ashley+N&rft.date=2019-02-01&rft.eissn=1360-0443&rft.volume=114&rft.issue=2&rft.spage=278&rft_id=info:doi/10.1111%2Fadd.14459&rft_id=info%3Apmid%2F30276906&rft.externalDocID=30276906
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0965-2140&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0965-2140&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0965-2140&client=summon